Skip to main content

ImmunoGen Value Stock - Dividend - Research Selection


ISIN: US45253H1014 , WKN: 878613

Market price date:
Market price:  

Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Key figures
Cash flow
Balance sheet
Income statement
Div. Yield%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization USD
Raw Data Source
Stock Split

Description of the company

ImmunoGen, Inc., a clinical-stage biotechnology company, focuses on developing antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; IMGN779 that is in Phase I clinical trial for the treatment of acute myeloid leukemia (AML); and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm, as well as coltuximab ravtansine, a CD19-targeting ADC, which is in Phase II trial for DLBCL. ImmunoGen, Inc. has collaborations with Roche; Bayer HealthCare AG; Sanofi; Biotest AG; Novartis Institutes for BioMedical Research, Inc.; Eli Lilly and Company; Amgen; CytomX Therapeutics, Inc.; Takeda Pharmaceutical Company Limited; Jazz Pharmaceuticals plc; and Debiopharm International SA. ImmunoGen, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,


Lyft’s stock rallies on strong forecasts. Here’s where the company is ‘doubling down.’

Ride-hailing platform Lyft Inc. on Tuesday said that it expected two key demand metrics to come in above Wall Street’s expectations for the year ahead, and...

Imperial Petroleum 4Q Rev $29.9M >IMPP


Silicon Laboratories, Inc. (SLAB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

NEW YORK, NY / ACCESSWIRE / February 13, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Silicon...

AngloGold Ashanti Announces H2 2023 and FY2023 Results Conference Call

DENVER--(BUSINESS WIRE)--February 13, 2024-- AngloGold Ashanti plc ("AGA") will release its results for the year ended 31 December 2023 on Friday, 23...

New "Healthier Workplaces and Schools" eBook Designed to Help Employers Assess, Mitigate Risks of Airborne Infectious Diseases

FALLS CHURCH, Va.--(BUSINESS WIRE)--February 13, 2024-- As more employers are examining their workplace health protocols to minimize the risk of airborne...

CobbleStone Software Named as Contract Lifecycle Management (CLM) Technology Leader in the SPARK Matrix(TM) Report

CobbleStone Software is distinguished as a Leader in the SPARK Matrix Analysis of the CLM Market. PRINCETON, N.J., Feb. 13, 2024 /PRNewswire-PRWeb/ --...

Tri-Cities Intermodal Moves First Loads

Tri-Cities Intermodal Moves First Loads PR Newswire WALLULA, Wash., Feb. 13, 2024 WALLULA, Wash., Feb. 13, 2024 /PRNewswire/ -- Tri-Cities Intermodal has...

BioPharma Credit gets USD50.6 million from Abbvie's ImmunoGen purchase

BioPharma Credit PLC on Tuesday noted Abbvie Inc's completed acquisition of ImmunoGen Inc.BioPharma Credit is a London-based closed-ended investment company. It said it has received USD50.6...

ImmunoGen, Inc.(NasdaqGS: IMGN) dropped from S&P Biotechnology Select Industry Index

ImmunoGen, Inc. dropped from S&P Biotechnology Select Industry Index...

ImmunoGen, Inc.(NasdaqGS: IMGN) dropped from S&P TMI Index

ImmunoGen, Inc. dropped from S&P TMI Index...